目的 采用指纹图谱与一测多评相结合的方法测定白芷药材及其饮片中的6种指标性成分，分析全国评价性抽验所抽验白芷质量，不断完善和修订标准方法，保障公众用药安全有效。方法 依据法定标准进行检验，建立白芷饮片的HPLC指纹图谱，水合氧化前胡素、白当归素、氧化前胡素、佛手柑内酯、欧前胡素和异欧前胡素6个指标成分一测多评定量测定方法，进行方法学考察，对20批（S1~S20）白芷饮片进行多指标成分含量测定，最终判定白芷饮片的质量。结果 共收到239批白芷饮片，涉及189家生产企业。其中225批次合格，14批次不合格，总体合格率为94.1%。以一测多评方法建立以欧前胡素为参照同步测定白芷饮片中6种香豆素类成分含量的方法，可以解决对照品难得、检验周期长等问题，更好地反映药材质量。结论 所建立的方法可用于白芷饮片中水合氧化前胡素、白当归素、氧化前胡素、佛手柑内酯、欧前胡素和异欧前胡素6个化学成分的定性定量分析。通过本次抽验，发现白芷饮片仍然存在一些质量问题，应进一步加强监管。

Objective To analyze the quality of Angelicae Dahuricae Radix (ADR) from national drug evaluation sampling, continuously improve and revise the standard determination method, and ensure the safety of public drug use, six index components of ADR medicinal material and decoction pieces were determined by combining HPLC fingerprint chromatography and quantitative analysis of multi-components by single marker (QAMS). Methods The determination and exploratory study were carried out according to the National Standard. The establishment of steamed Angelicae dahurica HPLC fingerprint, method for multiple assessment of six index components to conduct a methodological survey determination of multi-index component content of 20 batches of Angelicae dahurica tablets, the final determination of the quality of Angelicae dahurica. Results A total of 239 batches of ADR were received from 189 enterprises, in which 225 batches were qualified and 14 batches were unqualified. The qualified rate was 94%. A method that determined content of six kinds of coumarin in ADR decoction pieces using imperatorin as control was established, which could solve the problem of difficulty in obtaining control and consuming long determination time. It would better indicate the drug quality. Conclusion The method we had established could be used in qualitative and quantitative analysis of oxypeucedanin hydrate, byakangelicin, oxypeucedanin, berapten, imperatorin and isoimperatorin in ADR decoction pieces. Through this random inspection, it is found that there were still some quality problems in ADR decoction pieces. The quality supervision of traditional Chinese medicine should be strengthened further.

R286.02